Rituxan Comes In Like A Lion With Two New Indications
FDA clears Genentech/Biogen Idec’s oncologic Rituxan for rheumatoid arthritis weeks after it was approved for first-line non-Hodgkins lymphoma.
FDA clears Genentech/Biogen Idec’s oncologic Rituxan for rheumatoid arthritis weeks after it was approved for first-line non-Hodgkins lymphoma.